Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) will present results of its Phase 1b study of PTX-100 in T-cell lymphomas during a poster presentation at the 5th World Congress…

Bioshares has a Speculative Buy Class B recommendation for Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) after the company released positive trial results from its Phase Ib study in…

Cancer remains one of the most pressing public health challenges worldwide, affecting millions of lives and compounding economic burdens along the way. The companies dedicated…

Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) has had its abstract for PTX-100 published on the American Society of Hematology (ASH) website ahead of the company’s presentation at…

Results of a Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) Phase 1b study in T cell lymphomas have been accepted for poster presentation at the prestigious American Society of Hematology…

The prestigious International Society of Cell and Gene Therapy (ISCT) will showcase two abstracts from Prescient Therapeutics Ltd (ASX:PTX) at its annual meeting in Paris, which runs…

The prestigious International Society of Cell and Gene Therapy (ISCT) will showcase two abstracts from Prescient Therapeutics Ltd (ASX:PTX) at its annual meeting in Paris, which runs…

Prescient Therapeutics Ltd (ASX:PTX) CEO Steven Yatomi-Clarke tells Proactive the company has been granted additional Orphan Drug Designation for PTX-100 for the treatment of T-cell lymphomas (TCL), including…